Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1747930 | 0.81 | KMT2A (0.66) | IDO1MAPTGAASMN1; SMN2CYP1A2 | |
| SCHEMBL13693551 | 0.80 | MAPT (0.62) | MAPTGAASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL2590098 | 0.80 | CYP1A2 (0.64) | MAPTGAASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5078028 | 0.80 | ALDH1A1 (0.74) | IDO1MAPTGAASMN1; SMN2CYP1A2 | |
| SCHEMBL11550071 | 0.80 | MAPT (0.67) | MAPTGAASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL6302055 | 0.78 | GAA (0.64) | IDO1MAPTGAASMN1; SMN2CYP1A2 | |
| SCHEMBL11277333 | 0.78 | MAPT (0.64) | MAPTGAASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL5435931 | 0.78 | IDO1 (1.00) | IDO1MAPTGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL23812525 | 0.77 | GAA (0.84) | MAPTGAASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL1276402 | 0.77 | GAA (0.84) | MAPTGAASMN1; SMN2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772263-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524842-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156586-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ADAMTS1, ADAMTS13, ADAMTS7 | IDO1 1233/4885MAPT 622/4885GAA 50/4885 |
| US-20070197564-A1 | Compounds for the treatment of inflammatory disorders | ADAMTS1, ADAMTS13, ADAMTS7 | IDO1 1233/4885MAPT 622/4885GAA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.